Some new bi- and ter-benzimidazole derivatives as topoisomerase I inhibitors

Farmaco

Volumn 58, Issue 7, 2003, Pages 497-507

  Alper, Sabiha ^a   Arpaci, Özlem Temiz ^a   Şener Aki, Esin ^a   Yalçin, Ismail ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Benzimidazoles; Inhibitors; Topoisomerase I

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DRUG ACTIVITY; HUMAN; HUMAN CELL; IC 50; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 0038121714     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(03)00042-9     Document Type: Article

References (58)

1. Wang J.C. Interaction between DNA and E. coli protein omega. J. Mol. Biol. 55:1971;523-533.
2. Champoux J.J., Dulbecco R. An activity from mammalian cells that untwists super helical DNA - a possible swivel for DNA replication. Proc. Natl. Acad. Sci. USA. 69:1972;143-146.
3. Gellert M., Mizuuchi K., O'Dea M.H., Nash H.A. An enzyme that introduces super helical turns into DNA. Proc. Natl. Acad. Sci. USA. 73:1976;3872-3876.
4. Liu L.F., Liu C.C., Albert B.M. T4 DNA topoisomerase. A new ATP-dependent enzyme essential for the initiation of T4 bacteriophage DNA replication. Nature. 281:1979;456-461.
5. Capranico G., Binaschi M., Borgnetto M.E., Zunino F., Palumbo M. A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. TIPS. 18:1997;323-329.
6. Rowe T.C., Chen G.L., Hsiang Y.H., Liu L.F. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res. 46:1986;2021-2026.
7. Tewey K.M., Rowe T.C., Yang L., Halligan B.C., Liu L.F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 226:1984;466-468.
8. Nelson E.M., Tewey K.M., Liu L.F. Mechanism of antitumor drugs. Poisoning of mammalian DNA topoisomerase II on DNA by an antitumor drug m-AMSA. Proc. Natl. Acad. Sci. USA. 81:1984;1361-1365.
9. Tewy K.M., Chen G.L., Nelson E.M., Liu L.F. Intercalative antitumor drugs interfere with the breakage-re-union reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259:1984;9182-9187.
10. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:1989;351-375.
11. Liu L.F., D'Arpa P. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance. Important Adv. Oncol. 1992:1992;79-89.
12. Andoh T., Ikeda H., Oguro M. Molecular biology of DNA Topoisomerases and its Application to Chemotherapy. 1993;377 CRC Press, Boca Raton, Fla.
13. Xu Z., Li T.K., Kim J.S., LaVoie E.J., Breslauer K.J., Liu L.F., Pilch D.S. DNA Minor groove binding-directed poisoning of human DNA topoisomerase I by terbenzimidazoles. Biochemistry. 37:1998;3558-3566.
14. Hertzberg R.P., Busby R.W., Caranfa M.J., Holden K.G., Johnson R.K., Hecht S.M., Kingsbury W.D. J. Biol. Chem. 265:1990;19287-19295.
15. Pommier Y., Kohlhagen G., Kohn K.W., Leteurtre F., Wani M.C., Wall M.E. Proc. Natl. Acad. Sci. USA. 92:1995;8861-8865.
16. Hsiang Y.H., Hertzberg R.P., Hecht S.M., Liu L.F. J. Biol. Chem. 260:1985;14873-14878.
17. Hertzberg R.P., Hecht S.M., Caranfa M.J. Biochemistry. 28:1989;4629-4638.
18. Porter S.E., Chanpoux J.J. Nucleic Acids Res. 17:1989;8521-8532.
19. Nitiss J.L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochem. Biophys. Acta. 1400:1998;63-81.
20. Tobey R.A., Oishi N., Crissman H.A. Cell cycle synchronization: reversible induction of G2 synchrony in cultured rodent and human diploid fibroblasts. Proc. Natl. Acad. Sci. USA. 87:1990;5104-5108.
21. Woynarowski J.M., McHugh M., Sigmund R.D., Beerman T.A. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4′,6-aiamine-2-phenylindole. Mol. Pharmacol. 35:1989;177-182.
22. McHugh M., Woynarowski J.M., Sigmund R.D., Beerman T.A. Effect of minor groove binding drugs on mammalian topoisomerase I activity. Biochem. Pharmacol. 38:1989;2323-2328.
23. Kühholzer B., Prather S.R. Synchronization of porcine fetal fibroblast cells with topoisomerase-inhibitor Hoechst 33342. Anim. Reprod. Sci. 66:2001;109-116.
24. Wall M.E., Wani M.C., Cooke C.E., Palmer K.H., McPhail A.T., Slim G.A. The isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88:1966;3888-3890.
25. Hertzberg R.P., Caranfa M.J., Holdern K.G., Jakas D.R., Gallagher G., Mattern M.R., Mong S.-M., Bartus O.J., Johnson K.R., Kingsbury W.D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 32:1989;715-720.
26. Trask D.K., Muller M.T. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc. Natl. Acad. Sci. USA. 85:1988;1417-1421.
27. Wassermann K., Markovitz J., Jaxel C., Capranico G., Kohn K.W., et al. Effects of morpholinyl doxorubicins, doxorubucin, and actinomycin-D on mammalian DNA topoisomerase I and II. Mol. Pharmacol. 38:1990;38-45.
28. Chen A.Y., Yu C., Bodley A., Peng L.F., Liu L.F. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res. 53:1993;1332-1337.
29. Chen A.Y., Yu C., Gatto B., Liu L.F. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. USA. 90:1993;8131-8135.
30. Fujii N., Yamashita Y., Saitoh Y., Nakano H. Induction of mammalian DNA topoisomerase I-mediated DNA cleavage and DNA winding by bulgarein. J. Biol. Chem. 268:1993;13160-13165.
31. Yamashita Y., Fujii N., Murakata C., Ashizawa T., Okabe M., Nakano H. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry. 31:1992;12069-12075.
32. Yoshinari T., Yamada A., Uemura D., Nomura K., Akawa H., Kojiri K., Yoshida E., Suda H., Okura A. Induction of topoisomerase I mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res. 53:1993;490-494.
33. Allan Y.C., Liu L.F. DNA topoisomerases. Annu. Rev. Pharmacol. Toxicol. 34:1994;191-218.
34. Riou J.F., Helissey P., Grondard L., Giorgi-Renault S. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives. Mol. Pharmacol. 40:1991;699-706.
35. Anizon F., Belin L., Moreau P., Sancelme M., Voldoire A., Prudhomme M., Ollier M., Severe D., Riou J.F., Bailly C., Fabbro D., Meyer T. Syntheses and biological activities of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J. Med. Chem. 40:1997;3456-3465.
36. Pindur U., Lemster T. Antitumor drug design: DNA binding ligands, which inhibit the topoisomerase I. Pharmazie. 53:1998;79-86.
37. Poddevin B., Riou J.F., Lavelle F., Pommier Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new anti tumor agent in early clinical trials. Mol. Pharmacol. 44:1993;767-774.
38. Riou J.F., Fosse P., Nguyen C.H., Larsen A.K., Bissery M.C., Grondard L., Saucier J.M., Bisagni E., Lavelle F. Intoplicine (RP-60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Cancer Res. 53:1993;5987-5993.
39. Finlay J.G., Baguley C.B. Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II. Eur. J. Cancer. 26:1990;586-589.
40. Zhou R., Skibo E.B. Chemistry of pyrrolo[1,2-a]benzimidazole antitumor agents: Influence of the 7-substituent on the ability to alkylate DNA and inhibit topoisomerase II. J. Med. Chem. 39:1996;4321-4331.
41. Skibo E.B., Gordon S., Bess L., Boruah R., Heileman M.J. Studies of pyrrolo[1,2-a]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation. J. Med. Chem. 40:1997;1327-1339.
42. Settimo A., Settimo F., Marini A.M., Primofiore G., Magno S.M. Synthesis, DNA binding and invitro antiproliferative activity of purinoquinazoline, pyridopyrimidopurine and pyridopyrimidobenzimidazole derivatives as potential antitumor agents. Eur. J. Med. Chem. 33:1998;685-696.
43. Skibo E.B., Schultz W.G. Inhibitors of topoisomerase II based on the benzodiimidazole and dipyrroloimidazobenzimidazole ring systems. J. Med. Chem. 43:2000;629-638.
44. Tolner B., Hartley J.A., Hochhauser D. Transcriptional regulation of topoisomerase II a at confluence and pharmacological modulation of expression by bis-benzimidazole drugs. Mol. Pharmacol. 59:2001;699-706.
45. Sun Q., Gatto B., Yu C., Liu A., Liu L.F., LaVoie E.J. Structure activity of topoisomerase I poisons related to Hoechst 33342. Bioorg. Med. Chem. Lett. 4:1994;2871-2876.
46. Sun Q., Gatto B., Yu C., Liu A., Liu L.F., LaVoie E.J. Synthesis and evaluation of terbenzimidazoles as topoisomerase I inhibitors. J. Med. Chem. 38:1995;3638-3644.
47. Kim J.S., Yu C., Liu A., Liu L.F., LaVoie E.J. Terbenzimidazoles: influence of 2″-, 4- and 5-substituents on cytotoxicity and relative potency as topoisomerase I poisons. J. Med. Chem. 40:1997;2818-2824.
48. Kim J.S., Yu C., Liu A., Liu L.F., LaVoie E.J. Quantitative structure-activity relationships on 5-substituted terbenzimidazoles as topoisomerase I poisons and antitumor agents. Bioorg. Med. Chem. 6:1998;163-172.
49. Rangarajan M., Kim J.S., Yu C., Liu A., Liu L.F., LaVoie E.J., et al. 2″-Substituted 5-phenylterbenzimidazoles as topoisomerase I poisons. Bioorg. Med. Chem. 8:2000;1371-1382.
50. Rangarajan M., Kim J.S., Sim S.P., Liu A., Liu L.F., LaVoie E.J. Topoisomerase I inhibition and cytotoxicity of 5- bromo- and 5-phenylterbenzimidazoles. Bioorg. Med. Chem. 8:2000;2591-2600.
51. Zhang X., Kiechle F. Hoechst 33342-induced apoptosis is associated with decreased immunoreactive topoisomerase I and topoisomerase I-DNA complex formation. Ann. Clin. Lab. Sci. 31:2001;187-198.
52. Kim J.S., Gatto B., Yu C., Liu A., Liu L.F., LaVoie E.J. Substituted 2,5′-bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity. J. Med. Chem. 39:1996;992-998.
53. Jin S., Kim J.S., Sim S.P., Liu A., Pilch D.S., Liu L.F., LaVoie E.J. Heterocyclic bibenzimidazole derivatives as topoisomerase I inhibitors. Bioorg. Med. Chem. Lett. 10:2000;719-723.
54. Kim J.S., Gatto B., Yu C., Liu A., Liu L.F., LaVoie E.J., Sun Q. Structure-activity relationships of benzimidazoles and related heterocycles as topoisomerase I poisons. Bioorg. Med. Chem. 4:1996;621-630.
55. Temiz Ö., Ören I., Sener E., Yalçin I., Uçartürk N. Synthesis and microbiological activity of some novel 5- or 6-methyl-2-(2,4-disubstituted phenyl) benzoxazole derivatives. Il Farmaco. 53:1998;337-341.
56. Yalçin I., Sener E., Özden T., Özden S., Akin A. Synthesis and microbiological activity of 5-methyl-2-(p-substituted phenyl) benzoxazoles. Eur. J. Med. Chem. 25:1990;705-708.
57. Ören I., Temiz Ö., Yalçin I., Sener E., Akin A. Synthesis and microbiological activity of 5(or 6)-methyl-2-substituted benzoxazole and benzimidazole derivatives. Arzneimittel-Forschung/Drug Res. 47:1997;1393-1397.
58. Ören I., Temiz Ö., Yalçin I., Sener E., Altanlar N. Synthesis and microbiological activity of some novel 2,5- and/or 6-substituted benzoxazole and benzimidazole derivatives. Eur. J. Pharm. Sci. 7:1998;153-160.